Cell atlas of tropical disease parasite may hold key to new treatments
The atlas of 13 distinct cell types at the start of the Schistosoma mansoni's development will aid vaccine and treatment research
The first cell atlas of an important life stage of Schistosoma mansoni, a parasitic worm that poses a risk to hundreds of millions of people each year, has been developed by researchers at the Wellcome Sanger Institute and their collaborators.
The study, published today (18 December 2020) in Nature Communications, identified 13 distinct cell types within the worm at the start of its development into a dangerous parasite, including new cell types in the nervous and muscular systems. The atlas provides an instruction manual for better understanding the biology of S. mansoni that will enable research into new vaccines and treatments.
S. mansoni has a complex life cycle that begins when larval forms of the parasite emerge from snails into rivers and lakes. These larvae then enter humans through the skin after contact with infested water. Once inside the body, the parasite begins what is known as the intra-mammalian stage of its life cycle, undergoing a series of developmental transitions as it matures to adulthood.
Adult worms live in human blood vessels and reproduce, releasing eggs that pass from the body into water to continue the life cycle. But some eggs remain trapped in the body, leading to the disease schistosomiasis.
Schistosomiasis is a debilitating long-term illness that can lead to the inability to work, organ damage and death. It affects hundreds of millions of people each year, primarily in sub-Saharan Africa,* and is listed by the World Health Organisation (WHO) as one of the most Neglected Tropical Diseases. Currently, only one drug is available to treat the disease, but this is inappropriate for use in very young children and there are fears that overreliance on a single treatment will allow the parasites to develop resistance to the drug.
Researchers have been looking at ways to find new drug targets, but until now there has been no high-resolution understanding of the parasite’s biology.
This new study sought to map all of the cells in the first intra-mammalian stage of the parasite using single-cell technology, which identifies different cell types present in an organism or tissue.
The early-stage parasites were broken apart into individual cells that were characterised by single-cell RNA sequencing by scientists at the Wellcome Sanger Institute. The data were then analysed to identify cell types according to the genes expressed by individual cells, and where in the body these cells were located.
The team identified 13 distinct cell types, including previously unknown cell types in the nervous system and parenchymal system**. Individual fluorescent probes were made for genes specifically expressed by each cell type. Scientists at the Morgridge Institute for Research in the USA then used these probes to confirm the position of the discovered cells within whole parasites under the microscope.
“Though significant advances in our understanding of Schistosoma mansoni have been made in recent years, we have yet to identify targets leading to a viable vaccine. Single-cell RNA sequencing provides a whole new level of biological detail, including previously unidentified cell types, that will allow us to better understand each cell population in the parasite.”
Dr Carmen Diaz Soria, a first author of the study from the Wellcome Sanger Institute
To identify new drug targets, researchers most often look for differences between a pathogen and its human host. However, S. mansoni is far closer to us in evolutionary terms than most major parasites, such as those that cause malaria. It is hoped that these findings will reveal areas of the parasite’s genetic code that are sufficiently different from our own to be viable treatment targets.
“We found genes in the muscular system of Schistosoma mansoni that might be specific to schistosomes. Because they are found in these parasites but not in humans, they are one possible treatment target identified by the study. The muscle allows the parasite to travel through our bodies, so if we were able to hinder that ability, we may be able to halt its life cycle before reproduction takes place.”
Dr Jayhun Lee, a first author of the study from the Morgridge Institute for Research, Wisconsin USA
The authors also shed light on the parenchymal tissue of S. mansoni, the ‘filler’ tissue that connects all the tissues of the parasite together. Previous studies had found it difficult to isolate parenchymal cells for analysis. The cell atlas found that some genes that are important for the parasite to digest food are also associated with the parenchymal tissue. Disrupting how the parasite feeds by targeting these cells could be another avenue for therapies.
“Schistosomiasis is one of the most serious neglected parasitic diseases and gaining a deeper understanding of the parasite’s biology will help to expose vulnerabilities that could one day be targeted by new treatments. We hope that this cell atlas for the first intra-mammalian stage of Schistosoma mansoni will provide researchers with valuable clues to help accelerate the development of new treatments and eliminate this parasite from the lives of hundreds of millions of affected people each year.”
Dr Matt Berriman, senior author of the paper from the Wellcome Sanger Institute
* The World Health Organization has more information on the causes and effects of schistosomiasis. 229 million people received preventative treatment for the disease in 2018, with 393 million at risk of infection. https://www.who.int/news-room/fact-sheets/detail/schistosomiasis
** Parenchyma is the ‘filler’ tissue in the centre of the parasite that connects all the tissues together.
Carmen Lidia Diaz Soria, Jayhun Lee and Tracy Chong et al. (2020). Single-cell atlas of the first intra-mammalian developmental stage of the human parasite Schistosoma mansoni. Nature Communications. DOI: https://doi.org/10.1038/s41467-020-20092-5
This work was supported by Wellcome.
As an independent research organization, the Morgridge Institute for Research explores uncharted scientific territory to discover tomorrow’s cures. In affiliation with the University of Wisconsin-Madison, we support researchers who take a fearless approach to advancing human health in emerging fields such as regenerative biology, metabolism, virology and medical engineering. Through public programming, we work to inspire scientific curiosity in everyday life. Learn more at: www.morgridge.org
The Wellcome Sanger Institute is a world leading genomics research centre. We undertake large-scale research that forms the foundations of knowledge in biology and medicine. We are open and collaborative; our data, results, tools and technologies are shared across the globe to advance science. Our ambition is vast – we take on projects that are not possible anywhere else. We use the power of genome sequencing to understand and harness the information in DNA. Funded by Wellcome, we have the freedom and support to push the boundaries of genomics. Our findings are used to improve health and to understand life on Earth. Find out more at www.sanger.ac.uk or follow us on Twitter, Facebook, LinkedIn and on our Blog.
Wellcome exists to improve health by helping great ideas to thrive. We support researchers, we take on big health challenges, we campaign for better science, and we help everyone get involved with science and health research. We are a politically and financially independent foundation. https://wellcome.org/
14 Sep 2021
Evidence-based national policies are essential to curb local COVID-19 infections
By using genomic surveillance and mobile phone data, researchers have uncovered useful insights into the management of the COVID-19 pandemic in ...
10 Sep 2021
Wellcome Sanger Institute recognised as Charity Times finalist for outstanding contribution to pandemic response
Staff praised for dedication and excellence as they work to sequence coronavirus genomes, helping to shape the pandemic response